Greg Stanley Email & Phone Number

Charlotte, Nc, Us

Blacksburg, Va, Us

Private Equity owned, TechLab, Inc. (www.techlab.com) is a leading developer and manufacturer of infectious disease diagnostics products in the United States. Founded in 1989, the Company is headquartered in Blacksburg, VA and has a state-of-the-art manufacturing facility in Radford, VA. TechLab’s patented QUIK CHEK® rapid tests deliver extremely accurate results in 30 minutes. The Company has a market leading portfolio of diagnostic tests for infectious diseases including C. difficile (C. Diff) bacteria, parasitology and inflammation. TechLab products were globally distributed by Alere till 2021 and now directly through a global network of distributors. In August, 2022 TechLab merged with SSI Diagnostica.

Leeds, Yorkshire, Gb

Oncimmune is an oncology company focused on the early detection of cancer. The proprietary molecular platform was developed at the academic level in the UK with release as a commercial venture in 2003. Early focus was on the early detection of breast cancer. Oncimmune commercially released EarlyCDT-Lung, a test to aid in the early detection of lung cancer for at risk patients, on a pilot basis in 2009. As reimbursement and key publications became available, a full release in the Western Hemisphere followed in 2010 with European release in 2011.

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://clinical.opko.com/

Leeds, Yorkshire, Gb

About Oncimmune:Oncimmune is an oncology company focused on the early detection of cancer. The proprietary molecular platform was developed at the academic level in the UK with release as a commercial venture in 2003. Early focus was on the early detection of breast cancer. Oncimmune commercially released EarlyCDT-Lung, a test to aid in the early detection of lung cancer for at risk patients, on a pilot basis in 2009. As reimbursement and key publications became available, a full release in the Western Hemisphere followed in 2010 with European release in 2011.Since the 2010 release of EarlyCDT-Lung there are 19 peer-review publications, dozens of posters/presentations from key conferences, 2000+ primary care physicians and pulmonologists utilizing the test resulting in tens of thousands of commercial patient results being reported and numerous early stage lung cancers identified. Patient blood samples are analyzed in Oncimmune's metro Kansas City CLIA certified laboratory and reported back to the clinician.A key component of Oncimmune triple digit growth over the last 3 years has been the development of several international and US strategic partnerships; with several more in process. An ongoing commercial audit of clinical data from 1600 patients tested by EarlyCDT-Lung shows its utility in detecting early stage lung cancer and its overall performance. There are two ongoing randomized clinical trials. The Scottish NHS is conducting a 10,000 patient trial to validate the economics as a high risk screen and a 1600 patient study at National Jewish is comparing EarlyCDT-Lung and CT scans for pulmonary nodule determinations. Both studies began in 2012 and initial outcomes are expected in the near future. Oncimmune is developing an extensive pipeline for other solid tumor cancers, with a hepatocellular carcinoma test projected for 2014. For more information visit our clinical site www.Oncimmune.com or our patient educational site www.HelloHaveYouHeard.com .

Switzerland 🇨🇭 , Ch

Marketing RoleDirected sales of an extensive IVD product portfolio through the effective leadership of a sales and marketing team. Responsibilities included the launch of key new products, managing sizeable P&Ls and operational budgets and development of strategic and tactical plans. Corporate Account RoleManaged Roche Diagnostic sales on a corporate basis to Novation’s acute and non-acute care membership and led a multi-divisional sales and marketing organization on implementation of the contracting portfolio, creation of marketing programs and focused segmentation to drive sizable year over year increases. In addition, as part of the overall strategy, led an Integrated Health Network (IHN) sales team and managed a multi-million dollar operational budget.

Led the company’s commercial operations including leadership of a 100 member sales/service organization. Managed the P&L, a $20M budget and led a 20 member internal team including Marketing, Customer Service, Training, and Telemarketing. Also directly oversaw the IHN, Critical Care and Distribution teams. Secured over 650-instrument placements-$8M in capital sales.

Emeryville, California, Us

Abbott Park, Illinois, Us